Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure-Reference-Cited by-同舟云学术

Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure

Published:2022-11 Issue:19 Volume:80 Page:1775-1784
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Vaduganathan Muthiah,Claggett Brian L.,Jhund Pardeep,de Boer Rudolf A.,Hernandez Adrian F.,Inzucchi Silvio E.,Kosiborod Mikhail N.,Lam Carolyn S.P.,Martinez Felipe,Shah Sanjiv J.,Desai Akshay S.,Lindholm Daniel^ORCID,Petersson Magnus,Langkilde Anna Maria,McMurray John J.V.^ORCID,Solomon Scott D.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference19 articles.

1. Health status trajectories before and after hospitalization for heart failure;Vaduganathan;Circulation,2022

2. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes;Shah;J Am Coll Cardiol,2017

3. Dapagliflozin in heart failure with a mildly reduced or preserved ejection fraction;Solomon;N Engl J Med,2022

4. Empagliflozin in heart failure with a preserved ejection fraction;Anker;N Engl J Med,2021

5. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines;Heidenreich;J Am Coll Cardiol,2022

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating Mitral TEER in the Management of Moderate Secondary Mitral Regurgitation Among Heart Failure Patients;JACC: Heart Failure;2024-09

2. The contemporary role of sodium-glucose co-transporter 2 inhibitor (SGLT2i) and angiotensin receptor-neprilysin inhibitor (ARNI) in the management of heart failure: State-of-the-art review;Indian Heart Journal;2024-07

3. Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity;Frontiers in Cardiovascular Medicine;2024-05-16

4. Age-specific mortality trends in heart failure over 25 years: a retrospective Danish nationwide cohort study;The Lancet Healthy Longevity;2024-05

5. Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria;Circulation;2023-11-12